GIP and obesity disorder: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) regulate glucose homeostasis and are recognized as important therapeutic targets for diabetes and obesity (15, 16).